Noveris Health Sciences is trading 12.12% down now at CA$0.14, with the sharper explanation appearing to be continued profit-taking across biotech following recent extreme volatility.
- It announced a proposed private placement of convertible debentures for up to CA$500,000.
- The financing carries 10% annual interest and may convert into shares and warrants; the announcement does not explicitly attribute the decline to dilution or the stock’s movement.
- The biotech sector fell 2.47% during regular trading.